Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...

LEAD Agua Dulce, a tuition-free public charter school, is proud to launch the Campus Legacy Project, a school-wide, ...